Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pegaptanib sodium, an RNA aptamer specifically targeting vascular endothelial growth factor (VEGF)-165, holds great promise for investigating neovascular age-related macular degeneration (AMD).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry | |
10 mg | Inquiry | Inquiry |
Description | Pegaptanib sodium, an RNA aptamer specifically targeting vascular endothelial growth factor (VEGF)-165, holds great promise for investigating neovascular age-related macular degeneration (AMD). |
In vitro | Pegaptanib impedes the VEGF165-induced phosphorylation of VEGFR2 and phospholipase Cγ, and also obstructs VEGF165-triggered calcium mobilization in human umbilical vein endothelial cells[1]. |
Molecular Weight | N/A |
CAS No. | 222716-86-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pegaptanib sodium 222716-86-1 inhibitor inhibit